Liquidia (NASDAQ:LQDA) Chief Commercial Officer Scott Moomaw reported the exercise and immediate sale of 80,000 shares of common stock, according to a SEC Form 4 filing.
Metric | Value |
|---|---|
Shares sold (direct) | 80,000 |
Transaction value | ~$2.8 million |
Post-transaction shares (direct) | 188,954 |
Post-transaction value (direct ownership) | ~$6.8 million |
Transaction value based on SEC Form 4 weighted average sale price ($35.32); post-transaction value based on March 9, 2026, price ($35.32).
How does the sale size compare to Moomaw’s recent trading history?
The 80,000-share sale is materially larger than his recent median sell transaction of 4,848.5 shares since January 2025, reflecting a single trade that accounts for a significant portion of his remaining capacity rather than a shift in ongoing cadence.What was the structure and rationale behind the transaction?
The filing indicates this was an option exercise with immediate sale, executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025, consistent with routine liquidity management for vested awards.What is the impact on Moomaw’s remaining position and potential future sales?
Direct common stock holdings declined by 29.74% to 188,954 shares, while 25,300 stock options remain outstanding and could be exercised for additional shares, supporting continued alignment with shareholders.What is the market context for this transaction?
The sale took place with Liquidia shares priced at around $35.32, following a 159.4% one-year total return as of March 9, 2026, and leaves Moomaw with a post-sale direct equity position valued at approximately ~$6.8 million.
Metric | Value |
|---|---|
Price (as of market close March 9, 2026) | $35.32 |
Market capitalization | $3.19 billion |
Revenue (TTM) | $158.32 million |
1-year price change | N/A |
* 1-year price change calculated using March 9, 2026 as the reference date.
Products and services include YUTREPIA, an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension, and the distribution of generic treprostinil injection in the United States.
The company generates revenue through the development, manufacture, and commercialization of proprietary and generic pharmaceutical products targeting unmet medical needs.
Primary customers are healthcare providers and institutions treating patients with pulmonary arterial hypertension and related conditions.
Liquidia is a biotechnology company focused on developing and commercializing therapies for rare and serious conditions, with a strategic emphasis on pulmonary arterial hypertension. The company leverages proprietary drug formulation technologies to address unmet patient needs and expand its portfolio. Liquidia’s competitive edge lies in its ability to innovate within the inhaled therapeutics market and efficiently bring new treatments to commercialization.
